Special Issue "Porcine Vaccines: Enhancing Health, Productivity, and Welfare"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 742

Special Issue Editor

Dr. Tongqing An
E-Mail Website
Guest Editor
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China
Interests: PRRSV; PRV; molecular epidemiology; vaccine; diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are delighted to invite you to submit your next publication to the journal Vaccines for a Special Issue entitled “Porcine Vaccines: Enhancing Health, Productivity, and Welfare”. Porcine reproductive and respiratory syndrome, porcine viral diarrhea, African swine fever, circovirus-related diseases, and others, seriously harm and restrict the healthy development of the pig industry. In recent years, many variants of porcine viruses have emerged and immunologically escaped from the current available vaccines, causing new challenges in the prevention of porcine diseases and required the updating of existing vaccines, antigens, or adjuvants. DIVA vaccines, multivalent vaccines, and antigen-precise-designed vaccines are the focus of current porcine vaccine research. In addition, oral, spray, and other needle-free vaccination delivery methods have seen strong demand for animal disease control in the future.

This Special Issue will focus on porcine vaccines, including vaccine design, development, effect evaluation, small-animal replacement models, DIVA, vaccination delivery methods, and so on. Original research articles, and comprehensive reviews are welcome. We look forward to receiving your contributions.

Prof. Dr. Tongqing An
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 5602 KiB  
Article
New Formulation of a Subunit Vaccine Candidate against Lawsonia intracellularis Increases Humoral and Cellular Immune Responses
Vaccines 2023, 11(12), 1817; https://doi.org/10.3390/vaccines11121817 - 04 Dec 2023
Viewed by 401
Abstract
Previously, we designed a subunit vaccine candidate based on three L. intracellularis antigens with promising results in pigs. In this study, antigens were produced individually to achieve an even antigen ratio in the formulation. The emulsion characterization included the drop size and the [...] Read more.
Previously, we designed a subunit vaccine candidate based on three L. intracellularis antigens with promising results in pigs. In this study, antigens were produced individually to achieve an even antigen ratio in the formulation. The emulsion characterization included the drop size and the mechanical and thermal stability. Immune response was evaluated by indirect and sandwich ELISAs, qPCR, and flow cytometry. The vaccine candidate’s safety was assessed by histopathology and monitoring the clinical behavior of animals. The average production yielded for the chimeric antigen as inclusion bodies was around 75 mg/L. The formulation showed mechanical and thermal stability, with a ratio Hu/Ho > 0.85 and a drop size under 0.15 nm. Antigens formulated at a ratio of 1:1:1 induced a significant immune response in inoculated pigs that persisted until the end of the experiment (week 14). The dose of 200 μg significantly activated cellular response measured by transcriptional and translational levels of cytokines. The cell proliferation assay revealed an increment of lymphocytes T CD4+ at the same dose. Animals gained weight constantly and showed proper clinical behavior during immunization assays. This research demonstrated the immunological robustness of the new subunit vaccine candidate against Porcine Proliferative Enteropathy evenly formulated with three chimeric antigens of L. intracellularis. Full article
(This article belongs to the Special Issue Porcine Vaccines: Enhancing Health, Productivity, and Welfare)
Show Figures

Figure 1

Back to TopTop